Open AccessEnhancing adoptive T‐cell therapy with fucoidan‐based IL ‐2 delivery microcapsules
Author(s) -
Jeon Eun Young,
Choi Dasom,
Choi Seunghyun,
Won Juyoung,
Jo Yunju,
Kim Hyebin,
Jung Youngmee,
Shin Sang Chul,
Min Hophil,
Choi Hae Woong,
Lee Myeong Sup,
Park Yoon,
Chung Justin J.,
Jin Hyungseung
Publication year - 2023
Publication title -
bioengineering and translational medicine
Language(s) - English
Resource type - Journals
ISSN - 2380-6761
DOI - 10.1002/btm2.10362
Subject(s) - tumor microenvironment , cancer research , adoptive cell transfer , t cell , chemistry , cytotoxic t cell , cd8 , cell therapy , immune system , immunology , cell , medicine , in vitro , biochemistry
Adoptive cell therapy (ACT) with antigen‐specific T cells is a promising treatment approach for solid cancers. Interleukin‐2 (IL‐2) has been utilized in boosting the efficacy of ACT. However, the clinical applications of IL‐2 in combination with ACT is greatly limited by short exposure and high toxicities. Herein, a complex coacervate was designed to intratumorally deliver IL‐2 in a sustained manner and protect against proteolysis. The complex coacervate consisted of fucoidan, a specific IL‐2 binding glycosaminoglycan, and poly‐ l ‐lysine, a cationic counterpart (FPC 2 ). IL‐2‐laden FPC 2 exhibited a preferential bioactivity in ex vivo expansion of CD8 + T cells over Treg cells. Additionally, FPC 2 was embedded in pH modulating injectable gel (FPC 2 ‐IG) to endure the acidic tumor microenvironment. A single intratumoral administration of FPC 2 ‐IG‐IL‐2 increased expansion of tumor‐infiltrating cytotoxic lymphocytes and reduced frequencies of myeloid populations. Notably, the activation and persistency of tumor‐reactive T cells were observed only in the tumor site, not in the spleen, confirming a localized effect of FPC 2 ‐IG‐IL‐2. The immune‐favorable tumor microenvironment induced by FPC 2 ‐IG‐IL‐2 enabled adoptively transferred TCR‐engineered T cells to effectively eradicate tumors. FPC 2 ‐IG delivery system is a promising strategy for T‐cell‐based immunotherapies.